Skip to content

Jordi Bonaventura

3 papers in the library · 329 citations · publishing 2021-2025

Papers

Sort Most recent Most cited

Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?

The American journal of psychiatry March 1, 2025 Marjorie R Levinstein, Reece C Budinich, Jordi Bonaventura et al. 49 citations

Ketamine is a racemic compound and medication comprised of (S)-ketamine and (R)-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug. More recently, ketamine, its enantiomers, and its metabolites have been used or are being investigated for the treatment of refractory depression, as well as for comorbid disorders...

The dopaminergic effects of esketamine are mediated by a dual mechanism involving glutamate and opioid receptors.

Molecular Psychiatry February 19, 2025 Arianna Rizzo, Maria Zelai Garçon-Poca, Amelie Essmann et al. 14 citations

Esketamine represents a new class of drugs for treating mood disorders. Unlike traditional monoaminergic-based therapies, esketamine primarily targets N-methyl-D-aspartate receptors (NMDAR). However, esketamine is a complex drug with low affinity for NMDAR and can also bind to other targets, such as opioid receptors. Its precise mechanism of action for its antidepressant properties remains...

Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability

Molecular Psychiatry April 15, 2021 Jordi Bonaventura, Sherry Lam, Meghan L. Carlton et al. 266 citations

Ketamine, a racemic mixture of (S)-ketamine and (R)-ketamine enantiomers, has been used as an anesthetic, analgesic and more recently, as an antidepressant. However, ketamine has known abuse liability (the tendency of a drug to be used in non-medical situations due to its psychoactive effects), which raises concerns for its therapeutic use. (S)-ketamine was recently approved by the United...